Koppert invests in Amoéba to strengthen strategic collaboration
July 23, 2025
potential of this biofungicide,” says Martin Koppert, Chief Business Officer of Koppert. “We are committed to accelerating the adoption of biological [...] financially, validates the long-term value of our biocontrol technology,” adds Jean-François Doucet, CEO of Amoéba. “Together, we are unlocking a new chapter [...] through strategic partnership The biofungicide solution is based on the lysate of the amoeba Willaertia magna C2c, and is designed to combat fungal diseases